{
    "cancer_info": {
        "cancer_name": "Primary Cutaneous Lymphomas"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Skin biopsy (excisional, incisional, or punch)",
            "Immunohistochemistry (IHC) panel (CD20, CD3, CD5, CD10, BCL2, BCL6, IRF4/MUM1, FOXP1, CD2, CD4, CD7, CD8, CD30, TCRβ)",
            "Molecular studies (TCR/IgH gene rearrangement, NGS for MYD88/CD79B)",
            "Flow cytometry (peripheral blood for Sézary cell count and TRBC1 assessment)",
            "FDG-PET/CT or CT chest/abdomen/pelvis",
            "CBC with differential",
            "LDH testing",
            "Comprehensive metabolic panel",
            "HTLV-1/2 serology",
            "Lymph node biopsy (if adenopathy present)",
            "Bone marrow biopsy (for PCDLBCL-LT or cytopenias)",
            "Physical/skin exam with BSA assessment",
            "Pregnancy test (for childbearing-age individuals)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Early stage (IA-IIA)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "MF/SS",
                    "plan_name": "Skin-directed therapy",
                    "plan_details": "Topical corticosteroids, mechlorethamine, NB-UVB/PUVA phototherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Primary option"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PCFCL/PCMZL (T1-T2)",
                    "plan_name": "Involved-site RT",
                    "plan_details": "24–30 Gy radiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Primary option"
                }
            ]
        },
        {
            "staging_criteria": "Advanced stage (IIB-IV)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "CD30+ MF",
                    "plan_name": "Brentuximab vedotin",
                    "plan_details": "1.8 mg/kg IV every 3 weeks (max 16 cycles)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "MF/SS",
                    "plan_name": "Mogamulizumab",
                    "plan_details": "1 mg/kg IV weekly (cycle 1), then days 1+15 (subsequent cycles)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PCDLBCL-Leg Type",
                    "plan_name": "R-CHOP",
                    "plan_details": "Rituximab + cyclophosphamide/doxorubicin/vincristine/prednisone",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Primary regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory",
                    "patient_subgroup": "LCT MF/Visceral Disease",
                    "plan_name": "Gemcitabine or Liposomal doxorubicin",
                    "plan_details": "Variable dosing (low-dose preferred)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Erythrodermic MF (Stage III)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "B1/B2 blood involvement",
                    "plan_name": "Extracorporeal Photopheresis (ECP)",
                    "plan_details": "6+ months of therapy, often combined with interferon/retinoids",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Sézary Syndrome (Stage IVA)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Low blood burden (<5K/mm³)",
                    "plan_name": "Bexarotene or Romidepsin",
                    "plan_details": "Bexarotene: Variable dosing; Romidepsin: 14 mg/m² IV days 1,8,15 (28-day cycles)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "High blood burden (≥5K/mm³)",
                    "plan_name": "Mogamulizumab or Romidepsin",
                    "plan_details": "Mogamulizumab: 1 mg/kg IV weekly; Romidepsin: 14 mg/m² IV days 1,8,15",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Localized PCTLD (PC-ALCL)",
            "risk_group": "Localized",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Solitary/grouped lesions",
                    "plan_name": "Involved-site RT",
                    "plan_details": "20–35 Gy radiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Primary option"
                }
            ]
        },
        {
            "staging_criteria": "Multifocal PCTLD (PC-ALCL)",
            "risk_group": "Multifocal",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Skin-only disease",
                    "plan_name": "Brentuximab vedotin",
                    "plan_details": "1.8 mg/kg IV every 3 weeks",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "CD30: Predicts response to brentuximab vedotin (≥10% expression optimal; responses at any level); MYD88/CD79B mutations: Define 'MCD subtype' in PCDLBCL-LT and predict poor prognosis; CXCR3/Ig class-switching: IgG4+/CXCR3− indicates indolent PCMZL, IgM+/CXCR3+ predicts higher extracutaneous risk; TRBC1: Improves specificity for Sézary cell detection; FOXP1/IgM: Differentiates PCDLBCL-LT from PCFCL; CD25: ≥20% expression required for denileukin diftitox eligibility; Blood tumor burden (B2): Diagnostic for Sézary syndrome; ALK negativity: Distinguishes PC-ALCL from systemic ALCL; DUSP22-IRF4 rearrangement: Present in PC-ALCL/LyP without prognostic impact"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：原发性皮肤淋巴瘤.txt"
}